CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 752 enrolled
Drug / intervention
etanercept +2 moredrug
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Age 18 years or older
  • ✓Active psoriatic arthritis
  • ✓Clinically stable plaque psoriasis involving more than 10% of body surface area
Key exclusion· 3
  • ✕Skin conditions other than psoriasis that would interfere with skin examinations
  • ✕Systemic anti-psoriasis therapy or DMARD within 28 days of study drug initiation
  • ✕Prior exposure to any TNF inhibitor, including etanercept

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00245960
NCT00245960Phase 4Completed
CompareCT.gov

A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS

Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Oct 28, 2005·Updated Jan 31, 2022

In Brief

A Phase 4 clinical trial evaluating etanercept and Placebo for Psoriatic Arthritis. Completed, enrolled 752 participants across 120 sites in 26 countries.

Detailed Summary

The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesArgentina, Australia, Austria, Belgium, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Portugal, Saudi Arabia, Serbia and Montenegro, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 2005
Enrollment StartDec 27, 2005
Primary CompletionMar 29, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.7 years ago

Interventions

etanerceptdrug

etanerceptdrug

Placebodrug